Compare HDL & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HDL | DNA |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | Singapore | United States |
| Employees | 14003 | 485 |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.1M | 599.0M |
| IPO Year | N/A | N/A |
| Metric | HDL | DNA |
|---|---|---|
| Price | $12.66 | $9.03 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 1.3K | ★ 1.1M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $12.94 | N/A |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.00 | $5.37 |
| 52 Week High | $21.21 | $17.58 |
| Indicator | HDL | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 44.64 | 47.93 |
| Support Level | $12.00 | $7.59 |
| Resistance Level | $13.73 | $10.05 |
| Average True Range (ATR) | 0.13 | 0.83 |
| MACD | 0.03 | -0.12 |
| Stochastic Oscillator | 38.15 | 11.72 |
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.